Deanna Church | GenomeWeb

Deanna Church

Feb 05, 2016

10x Genomics has appointed Deanna Church as senior director of applications. Church will be utilizing the company's powerful Linked-Read data to develop methods for unlocking critical molecular and cellular information. She comes to the company from Personalis, where she served as senior director of genomics and content. Prior to that, Church worked for the National Center for Biotechnology for 14 years.

More Like This

Jan 20, 2017

Joshua Bilenker

Joshua Bilenker has resigned from the board of T2 Biosystems, effective immediately. 

According to a Form 8-K filed Jan. 20 with the US Securities and Exchange commission, he is resigning due to other personal commitments and not out of dispute or disagreement with T2 or the firm's management. 

Jan 19, 2017

Kevin Rosenblatt, Mary Lake Polan, Daniel Chan, Thomas McElrath

NX Prenatal has appointed Kevin Rosenblatt, Mary Lake Polan, Daniel Chan, and Thomas McElrath to its newly formed medical/clinical advisory board. Rosenblatt will serve as the chair and currently works as chief medical and scientific officer for the company. Prior to NX Prenatal, he served as chief medical officer/chief scientific officer of CompanionDx Labs. Polan is a clinical professor in the department of obstetrics and gynecology and reproductive science at Yale University School of Medicine. She also serves as chair emeritus of the department of obstetrics and gynecology at Stanford University. Chan is a professor of pathology, oncology, radiology, and urology at Johns Hopkins University School of Medicine. He also serves as director of the clinical chemistry division and co-director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore. McElrath is an associate professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School. He is also an attending physician at Brigham and Women's Hospital.

Jan 18, 2017

Mary Duseau, Paul Thomas

Roka Biosciences, a manufacturer of molecular diagnostics for foodborne pathogens, has named Mary Duseau as president and CEO. She succeeds Paul Thomas, who held those posts since 2009 and will now serve as chairman of the firm's board of directors. Duseau has been senior vice president and chief commercial officer at Roka since 2015. She was previously global sales director at Andor Technologies, a division of Oxford Instruments, and held various sales and management positions at PerkinElmer between 2000 and 2012. 

Jan 17, 2017

James Lewis

James Lewis has joined cancer genome testing firm Personal Genome Diagnostics as senior vice president of corporate development. He will oversee strategic planning, collaboration initiatives, and fundraising activities directed at securing capital to meet corporate objectives, including a planned Series B financing round this year. Lewis was previously VP of business development at Esperance Pharmaceuticals. Before that, he was at AstraZeneca, where he led business development work for the cardiovascular franchise and was on the Crestor commercial team. 

Jan 12, 2017

Francis Ouellette

Génome Québec has appointed Francis Ouellette as VP of scientific affairs. In this role, Ouellette will lead efforts to define the company's vision and develop its scientific strategy. He will start in his new role Feb. 27. Prior to his work with Génome Québec, Ouellette served as associate director of the informatics and biocomputing platform and lead investigator at the Ontario Institute for Cancer Research. He also served as associate professor in the department of medical genetics at the University of British Columbia, director of the UBC Bioinformatics Center at the Michael Smith Laboratories, and coordinated the GenBank database for the US National Institutes of Health.

Jan 11, 2017

Mark Adams

Jackson Laboratory has appointed Mark Adams as director of microbial genomic services. In this role, Adams will enhance the organization's large scale microbiome initiatives. Adams joins Jackson Laboratory from the J. Craig Venter Institute, where he directed programs that characterized genomic changes in antibiotic resistance. He also founded the Institute for Genomic Research, co-founded Celera Genomics, and served as associate professor of genetics at Case Western Reserve University.

Jan 09, 2017

Haywood Cochrane

Acuamark Diagnostics announced Haywood Cochrane has joined its board of directors. He will transition from his current position as a member of the firm's advisory board. Cochrane is currently a director at Corium and vice chair of the board at the University of North Carolina, Chapel Hill. Previously, he was CEO of CHD Meridian and was president and CEO of Allied Clinical Labs. 

Jan 09, 2017

Randy Scott, Sean George

Invitae President and Chief Operating Officer Sean George will take over as CEO, effective immediately, the company announced. Current CEO Randy Scott will continue full time at Invitae serving as executive chairman of the board of directors. The changes come as the company is focused on driving global growth in genetic testing. Previously, George was a co-founder and CEO of genetic analysis startup Locus Development. Scott previously served as executive chairman at Genomic Health and chief operating officer at personal genomics firm Navigenics.

Jan 06, 2017

Philip Bourne

The National Institutes of Health announced today that Philip Bourne will be leaving his post as associate director for data science effective April 30, 2017. Bourne joined the NIH in 2014 to lead the Big Data to Knowledge program. He will join the University of Virginia, Charlottesville as Stephenson Chair of data science, director of the Data Science Institute, and professor in the Department of Biomedical Engineering. 

Jan 06, 2017

Christian Henry

Ginkgo Bioworks has appointed Christian Henry to its board of directors. Henry joins from Illumina, where he served as executive VP and chief commercial officer. While at Ilumina, he also served as CFO, general manager of Life Sciences, and senior VP of corporate development. Before Illumina, he served as CFO of Tickets.com and VP of finance of Affymetrix.

Jan 06, 2017

Ian Clark

Guardant Health has appointed Ian Clark to its board of directors. Clark joins Guardant Health from Genetech, where he served as CEO, and Roche, where he led North American commercial operations. He has also held leadership roles at Novartis, Sanofi, and Ivax.

Jan 06, 2017

Troy Cox, Michael Pellini

Foundation Medicine announced that it has appointed Troy Cox as CEO to succeed Michael Pellini, who has been appointed as chairman of the board of directors. Pellini replaces Alexis Borisy, who will continue to serve on the board. Cox joins Foundation Medicine from Roche-Genetech, where he led one of the largest oncology portfolios in the US. Before joining Genentech, he held leadership positions at UCB BioPharma, Sanofi-Aventis, and Schering-Plough.

Jan 05, 2017

Stephanie Hallam

Claritas Genomics has appointed Stephanie Hallam as VP of molecular diagnostics. Hallam joins Claritas from Good Start Genetics, where she served as VP of laboratory operations and medical director.. She has also served in management and leadership positions at Genzyme Genetics, Athena Diagnostics, the University of Utah, and the University of Colorado.

Jan 05, 2017

Michael Nemzek

MedGenome has appointed Michael Nemzek as chief commercial officer. Nemzek has held executive leadership positions in both public companies and private companies, including RareCyte, Affymetrix, and Velocity11. He also holds advanced degrees in chemistry from North Carolina State University and in management from the University of Maryland.

Jan 05, 2017

Brady Davis, John Ellithorpe

DNAnexus expands its executive leadership team by appointing Brady Davis as vice president of strategy and marketing and John Ellithorpe as chief product officer. Davis comes to DNAnexus from Illumina, where he identified investment and acquisition opportunities, developed strategic partnerships, and led global product marketing for informatics. Before his work at Illumina, he led business development, strategy, and innovation for Oracle's Health Science Global Business Unit. Ellithorpe joins Illumina from Vantiq, where he served as chief product officer. Before his work at Vantiq, he co-founded Model N, where he served as chief technology officer and chief product officer.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.